suPAR Cut-Offs for Risk Stratification in Patients With Symptoms of COVID-19
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Standard
suPAR Cut-Offs for Risk Stratification in Patients With Symptoms of COVID-19. / Altintas, Izzet; Eugen-Olsen, Jesper; Seppälä, Santeri; Tingleff, Jens; Stauning, Marius Ahm; El Caidi, Nora Olsen; Elmajdoubi, Sanaá; Gamst-Jensen, Hejdi; Lindstrøm, Mette B.; Rasmussen, Line Jee Hartmann; Kristiansen, Klaus Tjelle; Rasmussen, Christian; Nehlin, Jan O.; Kallemose, Thomas; Hyppölä, Harri; Andersen, Ove.
I: Biomarker Insights, Bind 16, 2021, s. 1-12.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - suPAR Cut-Offs for Risk Stratification in Patients With Symptoms of COVID-19
AU - Altintas, Izzet
AU - Eugen-Olsen, Jesper
AU - Seppälä, Santeri
AU - Tingleff, Jens
AU - Stauning, Marius Ahm
AU - El Caidi, Nora Olsen
AU - Elmajdoubi, Sanaá
AU - Gamst-Jensen, Hejdi
AU - Lindstrøm, Mette B.
AU - Rasmussen, Line Jee Hartmann
AU - Kristiansen, Klaus Tjelle
AU - Rasmussen, Christian
AU - Nehlin, Jan O.
AU - Kallemose, Thomas
AU - Hyppölä, Harri
AU - Andersen, Ove
N1 - Publisher Copyright: © The Author(s) 2021.
PY - 2021
Y1 - 2021
N2 - Objectives: Elevated soluble urokinase Plasminogen Activator Receptor (suPAR) is a biomarker associated with adverse outcomes. We aimed to investigate the associations between plasma suPAR levels (testing the cut-offs ⩽4, 4-6, and ⩾6 ng/mL) with risk of 14-day mortality, and with the risk of mechanical ventilation in patients that tested positive for SARS-CoV-2. Methods: Observational cohort study of patients presenting with symptoms of COVID-19 at Department of Emergency Medicine, Amager and Hvidovre Hospital, Denmark from March 19th, 2020 to April 3rd, 2020. Plasma suPAR was measured using suPARnostic technologies. Patients were followed for development of mechanical ventilation and mortality for 14 days. Validation of our findings were carried out in a similar sized COVID-19 patient cohort from Mikkeli Central Hospital, Finland. Results: Among 386 patients with symptoms of COVID-19, the median (interquartile range) age was 64 years (46-77), 57% were women, median suPAR was 4.0 ng/mL (2.7-5.9). In total, 35 patients (9.1%) died during the 14 days follow-up. Patients with suPAR ⩽4 ng/mL (N = 196; 50.8%) had a low risk of mortality (N = 2; 1.0%; negative predictive value of 99.0%, specificity 55.3%, sensitivity 95.2%, positive predictive value 17.4%). Among patients with suPAR ⩾6 ng/mL (N = 92; 23.8%), 16 died (17.4%). About 99 patients (25.6%) tested positive for SARS CoV-2 and of those 12 (12.1%) developed need for mechanical ventilation. None of the SARS-CoV-2 positive patients with suPAR ⩽4 ng/mL (N = 28; 38.8%) needed mechanical ventilation or died. The Mikkeli Central Hospital validation cohort confirmed our findings concerning suPAR cut-offs for risk of development of mechanical ventilation and mortality. Conclusions: Patients with symptoms of COVID-19 and suPAR ⩽4 or ⩾6 ng/mL had low or high risk, respectively, concerning the need for mechanical ventilation or mortality. We suggest cut-offs for identification of risk groups in patients presenting to the ED with symptoms of or confirmed COVID-19.
AB - Objectives: Elevated soluble urokinase Plasminogen Activator Receptor (suPAR) is a biomarker associated with adverse outcomes. We aimed to investigate the associations between plasma suPAR levels (testing the cut-offs ⩽4, 4-6, and ⩾6 ng/mL) with risk of 14-day mortality, and with the risk of mechanical ventilation in patients that tested positive for SARS-CoV-2. Methods: Observational cohort study of patients presenting with symptoms of COVID-19 at Department of Emergency Medicine, Amager and Hvidovre Hospital, Denmark from March 19th, 2020 to April 3rd, 2020. Plasma suPAR was measured using suPARnostic technologies. Patients were followed for development of mechanical ventilation and mortality for 14 days. Validation of our findings were carried out in a similar sized COVID-19 patient cohort from Mikkeli Central Hospital, Finland. Results: Among 386 patients with symptoms of COVID-19, the median (interquartile range) age was 64 years (46-77), 57% were women, median suPAR was 4.0 ng/mL (2.7-5.9). In total, 35 patients (9.1%) died during the 14 days follow-up. Patients with suPAR ⩽4 ng/mL (N = 196; 50.8%) had a low risk of mortality (N = 2; 1.0%; negative predictive value of 99.0%, specificity 55.3%, sensitivity 95.2%, positive predictive value 17.4%). Among patients with suPAR ⩾6 ng/mL (N = 92; 23.8%), 16 died (17.4%). About 99 patients (25.6%) tested positive for SARS CoV-2 and of those 12 (12.1%) developed need for mechanical ventilation. None of the SARS-CoV-2 positive patients with suPAR ⩽4 ng/mL (N = 28; 38.8%) needed mechanical ventilation or died. The Mikkeli Central Hospital validation cohort confirmed our findings concerning suPAR cut-offs for risk of development of mechanical ventilation and mortality. Conclusions: Patients with symptoms of COVID-19 and suPAR ⩽4 or ⩾6 ng/mL had low or high risk, respectively, concerning the need for mechanical ventilation or mortality. We suggest cut-offs for identification of risk groups in patients presenting to the ED with symptoms of or confirmed COVID-19.
KW - biomarker
KW - COVID-19
KW - mechanical ventilation
KW - Prognosis
KW - suPAR
U2 - 10.1177/11772719211034685
DO - 10.1177/11772719211034685
M3 - Journal article
C2 - 34421295
AN - SCOPUS:85112725814
VL - 16
SP - 1
EP - 12
JO - Biomarker Insights
JF - Biomarker Insights
SN - 1177-2719
ER -
ID: 279632828